(Reuters) – Merck & Co’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company’s lead in the most lucrative oncology market.


Source: Reuters

Write a comment:

*
*Your email address will not be published

logo-footer

Designed & Developed by: Origamicx Digital Media